QURE - Conference and earnings call announcements

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Cowen Annual Healthcare Conference, March 6 – 8, 2023 Boston, MA Members of uniQure's management team, including Matt Kapusta, chief executive officer, will participate in one-on-one investor meetings on Monday, March 6.Mr. Kapusta also will participate in a panel discussion, "Genetic Medicines Corporate Panel," on March 6 from 10:30 – 11:30 a.m. ET. The live webcast of this eve

~ Achieved U.S. and European Commission marketing approvals of first and only gene therapyfor adults with hemophilia B ~ ~ Advancing development of AMT-130 for patients with Huntington's disease – clinical update from U.S. Phase I/II trial expected in second quarter 2023 ~ ~Hosted virtual investor event featuring AMT-260 in refractory temporal lobe epilepsy - expected to enter clinical development in second half of 2023 ~ ~Expanded pipeline with in-licensing of AMT-162 for SOD1 ALS - plans to initiate a Phase I/II clinical trial in the second half of 2023 ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 27, 2023 (GLOBE NEWSWIRE) --  uniQure N.V. (NASDAQ:QURE), a leading gene the

~ IND Submission and Clinical Development Expected to Begin in 2023 ~ ~ Advancements in Manufacturing and Technology Platform Also Highlighted ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 29, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, hosted a virtual investor event focused on AMT-260, an AAV gene therapy for refractory temporal lobe epilepsy (rTLE) and other focal epilepsies. The event featured a presentation from rTLE clinical expert Ellen Bubrick, MD, associate chair of Neurology at Harvard Medical School and director of the Epilepsy Surgery Program at Brigha

~ Patient enrollment at the higher dose of AMT-130 to resume in European Phase Ib/II study following Data Safety Monitoring Board recommendation ~~ U.S. and European pre-approval inspections of Company's Lexington, MA manufacturing site completed with EMA issuing Good Manufacturing Certificate ~~ Virtual investor event focused on next pipeline program, AMT-260 investigational gene therapy for refractory temporal lobe epilepsy, to be held on Tuesday, November 29, 2022 ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its fina

LEXINGTON, Mass. and AMSTERDAM, Oct. 03, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Chardan's 6th Annual Genetic Medicines Conference, October 3 – 4, 2022 Members of uniQure's management team, including Ricardo Dolmetsch, Ph.D., president of research and development, will participate in one-on-one investor meetings on Monday, October 3.A fireside chat with Dr. Dolmetsch will take place the same day from 8:30 to 8:55 a.m. ET. The live webcast of the fireside chat can be accesse

LEXINGTON, Mass. and AMSTERDAM, Sept. 06, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Citi's 17th Annual BioPharma Conference, September 7 – 8, 2022 Members of uniQure's management team, including Matt Kapusta, chief executive officer, and Ricardo Dolmetsch, Ph.D., president of research and development, will participate in one-on-one investor meetings on Wednesday, September 7th. Wells Fargo 2022 Healthcare Conference, September 7 – 9, 2022 Members of uniQure's management tea

LEXINGTON, Mass. and AMSTERDAM, Feb. 07, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington's disease. The clinical trial is taking place at several sites in Poland, the United Kingdom and Germany.    "We are very pleased to expand the clinical development of AMT-130 and to build on our ongoing experience in the Phase I/II clinical trial in the United States," stated Ricardo Dolmetsch, Ph.D.,

LEXINGTON, Mass. and AMSTERDAM, Nov. 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: The 28th Annual Meeting of the Huntington Study Group (Virtual), November 4 - 6, 2021 David Cooper, M.D., vice president of clinical research CNS, will present an overview of the ongoing clinical trials of AMT-130 in Huntington's Disease, HD-GeneTRX-1 and -2, and participate in a Q&A session on Friday, November 5th at 3:15 p.m. ET. An encore poster presentation entitled, "Demographics and healthca

LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Chardan's 5th Annual Genetic Medicines Conference, October 4 - 5, 2021 Members of uniQure's management team, including Matt Kapusta, chief executive officer, will participate in virtual one-on-one investor meetings the morning of Tuesday, October 5th.A fireside chat with Matt Kapusta will take place the same day from 8:00 to 8:30 a.m. ET. The live webcast of the fireside chat can be accessed thro

LEXINGTON, Mass. and AMSTERDAM, Sept. 07, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Citi's 16th Annual BioPharma Virtual Conference, September 8 - 10, 2021 Members of uniQure's management team, including Matt Kapusta, chief executive officer, will participate in virtual one-on-one investor meetings throughout the day on Thursday, September 9. Wells Fargo 2021 Virtual Healthcare Conference, September 9 - 10, 2021 Members of uniQure's management team will participate in virtual on

~ Expanded gene therapy pipeline with four new research programs and announced acquisitionof Corlieve Therapeutics ~ ~ Presented positive 52-week data from HOPE-B pivotal study demonstrating sustained increases in Factor IX (FIX) levels with mean FIX activity of 41.5 percent of normal and significant reductions in bleeding events ~ ~ Completed its global commercialization and license transaction with CSL Behring for hemophilia B gene therapy program ~ ~ Initiated patient enrollment in second dose cohort of Phase I/II clinical trial of AMT-130 for Huntington'sdisease, with initiation of a European Phase Ib/II clinical trial expected in second half of 2021 ~ LEXINGTON, Mass. and AMSTERDAM,

LEXINGTON, Mass. and AMSTERDAM, June 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences: Jefferies Virtual Healthcare Conference, June 1 - 4, 2021 Members of uniQure's management team will participate in virtual one-on-one investor meetings throughout the day on Wednesday, June 2.A fireside chat with Matt Kapusta, chief executive officer, will take place the same day from 8:30 to 8:55 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 03, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences: 7th Annual Truist Securities Life Sciences Summit, May 4 - 5, 2021 Members of uniQure's management team will participate in virtual one-on-one investor meetings throughout the day on Tuesday, May 4. American Society of Gene and Cell Therapy (ASGCT) Virtual 2021, May 11 - 14, 2021 uniQure will have a significant presence at ASGCT with five data presentations, of which two ar

LEXINGTON, Mass. and AMSTERDAM, April 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences: Virtual Guggenheim Healthcare Talks│2021 Genomic Medicines & Rare Disease, April 1, 2021 Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Thursday, April 1.Matt Kapusta, chief executive officer, will participate on a panel discussion entitled, “The Low-Hanging Fruit in Gene Therapy Might Be Hard to Reach – Challenges for

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 26, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences: Cowen 41st Annual Health Care Conference, March 1 - 4, 2021 Members of uniQure’s management team including Matt Kapusta, chief executive officer, and Ricardo Dolmetsch, Ph.D., president of research & development, will participate in virtual one-on-one investor meetings throughout the day on Monday, March 1.David Cooper, M.D., vice president of clinical research CNS, will

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences: 14th Annual Congress of the European Association of Hemophilia and Allied Disorders (EAHAD), February 3 – 5, 2021 • uniQure will deliver multiple presentations on the company’s gene therapy candidate etranacogene dezaparvovec in patients with hemophilia B. These presentations will include encore clinical data first presented at medical conferences late last year, as well

LEXINGTON, Mass. and AMSTERDAM, Dec. 21, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that its hemophilia B gene therapy program, including the pivotal, Phase III HOPE-B study, has been placed on clinical hold by the U.S. Food and Drug Administration (FDA).   Patient dosing is complete in each of uniQure’s three hemophilia B gene therapy studies, and there is no plan to enroll or treat additional patients. The clinical hold was initiated following the submission of a safety report in mid-December relating to a possibly related serious adverse event associated

LEXINGTON, Mass and AMSTERDAM, Dec. 02, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that its participation in the following upcoming virtual investor and scientific conferences: • Evercore ISI 3rd Annual HealthCONx Conference, December 1 - 3, 2020 A fireside chat with Ricardo Dolmetsch, Ph.D., president of research & development, will take place today, December 2, 2020 from 8:25 – 8:45 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available